115 related articles for article (PubMed ID: 38411303)
21. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
22. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
23. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
Luo L; Ji Y; Yu L; Huang Y; Liang X; Graham DY; Lu H
Dig Dis Sci; 2020 Dec; 65(12):3639-3646. PubMed ID: 32020360
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Park KN; Hahm JS; Kim HJ
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
[TBL] [Abstract][Full Text] [Related]
25. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
[TBL] [Abstract][Full Text] [Related]
26. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.
Federico A; Nardone G; Gravina AG; Iovene MR; Miranda A; Compare D; Pilloni PA; Rocco A; Ricciardiello L; Marmo R; Loguercio C; Romano M
Gastroenterology; 2012 Jul; 143(1):55-61.e1; quize e13-4. PubMed ID: 22484118
[TBL] [Abstract][Full Text] [Related]
28. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.
Scaccianoce G; Hassan C; Panarese A; Piglionica D; Morini S; Zullo A
Can J Gastroenterol; 2006 Feb; 20(2):113-7. PubMed ID: 16482238
[TBL] [Abstract][Full Text] [Related]
29. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
[TBL] [Abstract][Full Text] [Related]
30. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Tian XL; Suo BJ; Zhang H; Lu HP; Li CL; Zhang YX; Ren XL; Yao XY; Zhou LY; Song ZQ
Helicobacter; 2023 Feb; 28(1):e12935. PubMed ID: 36374159
[TBL] [Abstract][Full Text] [Related]
31. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial.
Kuo CH; Hsu PI; Kuo FC; Wang SS; Hu HM; Liu CJ; Chuah SK; Chen YH; Hsieh MC; Wu DC; Tseng HH
J Antimicrob Chemother; 2013 Jan; 68(1):222-8. PubMed ID: 22984204
[TBL] [Abstract][Full Text] [Related]
33. Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication.
Sjomina O; Lielause A; Rūdule A; Vangravs R; Paršutins S; Poļaka I; Daugule I; Stonāns I; Park JY; Leja M
Eur J Cancer Prev; 2022 Jul; 31(4):333-338. PubMed ID: 35471812
[TBL] [Abstract][Full Text] [Related]
34. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Wu DC; Hsu PI; Tseng HH; Tsay FW; Lai KH; Kuo CH; Wang SW; Chen A
Medicine (Baltimore); 2011 May; 90(3):180-185. PubMed ID: 21512411
[TBL] [Abstract][Full Text] [Related]
35. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.
Sánchez-Delgado J; García-Iglesias P; Castro-Fernández M; Bory F; Barenys M; Bujanda L; Lisozain J; Calvo MM; Torra S; Gisbert JP; Calvet X
Aliment Pharmacol Ther; 2012 Jul; 36(2):190-6. PubMed ID: 22591220
[TBL] [Abstract][Full Text] [Related]
36. High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection.
Hsu PI; Lai KH; Wu CJ; Tseng HH; Tsay FW; Peng NJ; Chen TA; Chuah SK; Lin WS; Lo GH
Eur J Clin Invest; 2007 Sep; 37(9):724-30. PubMed ID: 17696962
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
[TBL] [Abstract][Full Text] [Related]
38. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.
Song Z; Fu W; Zhou L
BMC Gastroenterol; 2019 Jul; 19(1):132. PubMed ID: 31345165
[TBL] [Abstract][Full Text] [Related]
39. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Kiliç ZM; Köksal AS; Cakal B; Nadir I; Ozin YO; Kuran S; Sahin B
Dig Dis Sci; 2008 Dec; 53(12):3133-7. PubMed ID: 18465244
[TBL] [Abstract][Full Text] [Related]
40. High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial.
Yun JW; Wang C; Yu Y; Xu HM; Gou LZ; Li XL; Yi GR; Lin YM; Han TY; Zhang DK
Br J Clin Pharmacol; 2023 Jan; 89(1):232-241. PubMed ID: 35947524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]